The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.

Related News Articles

Headline
The AHA today debuted a new video that spotlights the value of membership in the AHA, including how the association is telling hospital and health systems’…
Headline
The AHA has been featured in numerous media publications, including the Washington Post, Wall Street Journal, Politico and Modern Healthcare, for various COVID…
Blog
The AHA strives to ensure the hospital and health system field’s voice is heard in the news and media and any discussion of health care. The association…
Headline
In light of the latest novel coronavirus (COVID-19) developments and the unprecedented and still growing demand for health care, construction and architecture…
Headline
In light of the latest novel coronavirus (COVID-19) developments and the need for nursing leaders to remain onsite in their essential roles, the AHA and its…
Chairperson's File
Hospitals and health systems are working to address their patients’ social needs and the broader social determinants of health in the communities they serve.…